Patents by Inventor Liza Robles-Carrillo

Liza Robles-Carrillo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EFFECTOR-DEFICIENT ANTI-CD32A ANTIBODIES
    Publication number: 20190211097
    Abstract: Effector-deficient anti-CD32a monoclonal antibodies are encompassed, as are method and uses for treating CD32a-mediated diseases and disorders, including, thrombocytopenia, allergy, hemostatic disorders, immune, inflammatory, and autoimmune disorders.
    Type: Application
    Filed: November 29, 2018
    Publication date: July 11, 2019
    Inventors: John Francis, Ali Amirkhosravi, Todd Meyer, Liza Robles-Carrillo
  • Effector-deficient anti-CD32a antibodies
    Patent number: 10184001
    Abstract: Effector-deficient anti-CD32a monoclonal antibodies are encompassed, as are method and uses for treating CD32a-mediated diseases and disorders, including, thrombocytopenia, allergy, hemostatic disorders, immune, inflammatory, and autoimmune disorders.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: January 22, 2019
    Assignee: Adventist Health System/Sunbelt Inc.
    Inventors: John Francis, Ali Amirkhosravi, Todd Meyer, Liza Robles-Carrillo
  • EFFECTOR-DEFICIENT ANTI-CD32A ANTIBODIES
    Publication number: 20160347838
    Abstract: Effector-deficient anti-CD32a monoclonal antibodies are encompassed, as are method and uses for treating CD32a-mediated diseases and disorders, including, thrombocytopenia, allergy, hemostatic disorders, immune, inflammatory, and autoimmune disorders.
    Type: Application
    Filed: June 2, 2016
    Publication date: December 1, 2016
    Applicant: Adventist Health System/Sunbelt Inc.
    Inventors: John Francis, Ali Amirkhosravi, Todd Meyer, Liza Robles-Carrillo
  • Effector-deficient anti-CD32A antibodies
    Patent number: 9382321
    Abstract: Effector-deficient anti-CD32a monoclonal antibodies are encompassed, as are method and uses for treating CD32a-mediated diseases and disorders, including, thrombocytopenia, allergy, hemostatic disorders, immune, inflammatory, and autoimmune disorders.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: July 5, 2016
    Assignee: Adventis Health System/Sunbelt, Inc.
    Inventors: John Francis, Ali Amirkhosravi, Todd Meyer, Liza Robles-Carrillo
  • EFFECTOR-DEFICIENT ANTI-CD32A ANTIBODIES
    Publication number: 20160145336
    Abstract: Effector-deficient anti-CD32a monoclonal antibodies are encompassed, as are method and uses for treating CD32a-mediated diseases and disorders, including, thrombocytopenia, allergy, hemostatic disorders, immune, inflammatory, and autoimmune disorders.
    Type: Application
    Filed: November 26, 2014
    Publication date: May 26, 2016
    Applicant: ADVENTIST HEALTH SYSTEM/SUNBELT INC.
    Inventors: John Francis, Ali Amirkhosravi, Todd Meyer, Liza Robles-Carrillo
  • Assessment of Protein C Anticoagulant Pathway By Thrombin Generation Assay In The Presence of Endothelial Cells
    Publication number: 20140080160
    Abstract: The present application discloses the effects of endothelial cell-dependent activation of the protein C anticoagulant pathway via detection of thrombin generation correlated with the activation of the protein C anticoagulant pathway in plasma in the presence of endothelial cells using a fluorogenic substrate-based thrombin generation assay.
    Type: Application
    Filed: August 12, 2013
    Publication date: March 20, 2014
    Applicant: ADVENTIST HEALTH SYSTEM/SUNBELT, INC.
    Inventors: Enriqueta Coll, Liza Robles-Carrillo, John Francis, Ali Amirkosravi